Why the study?
Does adding aliskiren to an ACEI or ARB improve myocardial salvage and alter monocyte subsets in patients with primary acute myocardial infarction?
Does adding aliskiren to an ACEI or ARB improve myocardial salvage and alter monocyte subsets in patients with primary acute myocardial infarction?
Adding aliskiren to an ACEI or ARB significantly improves myocardial salvage 7 days after acute myocardial infarction compared to ACEI/ARB alone.
Answers are grounded in this paper and cite their sources.
Aliskiren addition to ACEI/ARB was associated with greater myocardial salvage post-MI; hypothesis-generating and requires randomized confirmation.
BACKGROUND: It remains unclear whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) have fully delivered the expected reduction in cardiovascular diseases. We investigated the effects of adding the direct renin inhibitor (DRI), aliskiren, to an ACEI or an ARB on monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction (AMI). METHODS AND RESULTS: Twenty-one consecutive patients were treated with an ACEI or an ARB (non-DRI group), and another 21 consecutive patients received aliskiren combined with an ACEI or an ARB (DRI group). Two monocyte subsets (CD14(+)CD16(-) and CD14(+)CD16(+)) were measured by flow cytometry. The extent of myocardial salvage 7 days after AMI was evaluated by cardiac magnetic resonance imaging. Both plasma renin activity and aldosterone levels were significantly lower in the DRI group than in the non-DRI group. Peak levels of CD14(+)CD16(-) monocyte number and ratio were also significantly lower in the DRI group. The extent of myocardial salvage was significantly higher in the DRI group than in the non-DRI group (44.8 [41.2-53.1] vs. 36.0 [28.5-42.6], P=0.001). CONCLUSIONS: A DRI combined with an ACEI or an ARB can better improve the extent of myocardial salvage after AMI than an ACEI or an ARB alone in association with the decrease in circulating CD14(+)CD16(-) monocytes.
No takes yet. Share an insight, caveat, or question.
Ozaki et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: